A scientific journal has retracted a controversial paper, published last year, that suggested the gene-editing tool CRISPR was a genome wrecking ball.

In the retracted study, researchers sought to use CRISPR in mice to correct a mutation that causes blindness. They successfully fixed the genetic error but reported that CRISPR inadvertently made more than a thousand other changes—potentially harmful ones—in the animals’ DNA.

It didn’t take long for the results, published in Nature Methods, to spark panic that CRISPR might be too dangerous to use in humans. The findings hadn’t been observed by other researchers and immediately drew criticism from people including executives at the big three gene-editing companies, CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics—whose stocks tumbled after the study was published.

Today, Nature Methods retracted the paper, saying in an accompanying editorial that “there was insufficient data to support the claim of unexpected off-target effects due to CRISPR.”

As the first clinical trials using CRISPR are ramping up in Europe and the US, that’s welcome news to companies and patients standing to benefit from the technology. In statements provided to MIT Technology Review, Editas and Intellia said they were pleased that the scientific process was able to “correct the record.”

CRISPR is a biological system that can be programmed to precisely cut segments of DNA. It’s been touted as a permanent cure for genetic diseases and as a more effective cancer treatment. But questions still remain about how safe it is and how well it could actually work in the body.